Deciphering HSA21 genes associated with Alzheimers disease in Down Syndrome
破译与唐氏综合症中阿尔茨海默病相关的 HSA21 基因
基本信息
- 批准号:10120793
- 负责人:
- 金额:$ 28.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-15 至 2023-09-14
- 项目状态:已结题
- 来源:
- 关键词:Administrative SupplementAge-YearsAlzheimer&aposs DiseaseAlzheimer&aposs disease riskAmyloidAmyloid beta-42Amyloid beta-ProteinBrainCRISPR/Cas technologyCandidate Disease GeneCell Culture TechniquesCell LineCellsChromosome 21Clustered Regularly Interspaced Short Palindromic RepeatsCodeCognitionComplementComplexDevelopmentDiseaseDown SyndromeEpigenetic ProcessFundingGene ClusterGene ProteinsGenesGeneticGenetic DiseasesGrantGuidelinesHumanIndianaIndividualLive BirthLongevityMessenger RNAMethodsMicroRNAsModelingMusMutationNeurofibrillary TanglesNeurologicNeuronsOpen Reading FramesPPBP genePathogenesisPathologicPeptidesPhenotypePilot ProjectsPresenile Alzheimer DementiaProteinsResource DevelopmentSubgroupTc1 mouseTechniquesTestingTimeUnited States National Institutes of HealthV717FWorkabeta accumulationbaseclinical developmentexperimental studyfallsgenetic risk factorhuman modelinduced pluripotent stem cellinterestknock-downmouse modelnovelnovel strategiestrait
项目摘要
Summary
Down syndrome arises from the triplication of a subset of genes on chromosome 21 (HSA21). Individuals with
DS uniformly demonstrate some degree early onset Alzheimers disease. Recent studies have suggested
triplication of genes on HSA21, other than APP, contribute to the disruption of beta amyloid (Abeta) processing
in mice. Whether similar pathological mechanisms are observed in human DS cells, as well as what subset of
HSA21 genes are responsible for this disruption, remain unknown. We have developed a simple but novel
approach using CRISPR gene editing techniques and DS cell culture models which will allow for knockdown of
a single HSA21 copy, while leaving the other two copies intact. With this approach, we can systematically
identify the subset of HSA21 genes most likely to contribute to the altered Abeta processing. Identification of
the subset of HSA21 genes most responsible for AD in DS is not only critical for understanding pathological
mechanisms, but also for devising appropriate therapies for treatment of this disorder.
摘要
唐氏综合症是由21号染色体(HSA21)上的一组基因的三倍体引起的。具有以下特征的个人
DS均表现为一定程度的早发性阿尔茨海默病。最近的研究表明
除APP外,HSA21上基因的三倍复制导致了β-淀粉样蛋白(Abeta)加工的中断
在老鼠身上。是否在人类DS细胞中观察到类似的病理机制,以及
HSA21基因是造成这种干扰的原因,目前尚不清楚。我们开发了一种简单但新颖的
使用CRISPR基因编辑技术和DS细胞培养模型的方法将允许敲除
一个HSA21拷贝,而其他两个拷贝保持不变。使用这种方法,我们可以系统地
确定HSA21基因的子集最有可能对改变的Abeta过程做出贡献。身份识别
HSA21基因的子集对DS中的AD负有最大的责任,这不仅对理解病理
这不仅有助于研究治疗这种疾病的机制,还有助于设计治疗这种疾病的适当疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VOLNEY L SHEEN其他文献
VOLNEY L SHEEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VOLNEY L SHEEN', 18)}}的其他基金
Down Syndrome: a potential treatment XISTs
唐氏综合症:一种潜在的治疗方法 XIST
- 批准号:
10525816 - 财政年份:2022
- 资助金额:
$ 28.19万 - 项目类别:
Epigenetic Silencing of HSA21 in Down Syndrome
唐氏综合症中 HSA21 的表观遗传沉默
- 批准号:
10016836 - 财政年份:2019
- 资助金额:
$ 28.19万 - 项目类别:
Epigenetic Silencing of HSA21 in Down Syndrome
唐氏综合症中 HSA21 的表观遗传沉默
- 批准号:
9892127 - 财政年份:2019
- 资助金额:
$ 28.19万 - 项目类别:
Cellular and Molecular Mechanisms in Periventricular Heterotopia
脑室周围异位的细胞和分子机制
- 批准号:
8269069 - 财政年份:2009
- 资助金额:
$ 28.19万 - 项目类别:
Cellular and Molecular Mechanisms in Periventricular Heterotopia
脑室周围异位的细胞和分子机制
- 批准号:
7729307 - 财政年份:2009
- 资助金额:
$ 28.19万 - 项目类别:
Cellular and Molecular Mechanisms in Periventricular Heterotopia
脑室周围异位的细胞和分子机制
- 批准号:
8078196 - 财政年份:2009
- 资助金额:
$ 28.19万 - 项目类别:
Cellular and Molecular Mechanisms in Periventricular Heterotopia
脑室周围异位的细胞和分子机制
- 批准号:
8470253 - 财政年份:2009
- 资助金额:
$ 28.19万 - 项目类别:
Human Neural Precursors from CNS Developmental Disorders: Down Syndrome
中枢神经系统发育障碍的人类神经前体:唐氏综合症
- 批准号:
7602965 - 财政年份:2008
- 资助金额:
$ 28.19万 - 项目类别:
Human Neural Precursors from CNS Developmental Disorders: Down Syndrome
中枢神经系统发育障碍的人类神经前体:唐氏综合症
- 批准号:
7470915 - 财政年份:2008
- 资助金额:
$ 28.19万 - 项目类别:
The Role of Filamin in Periventricular Heterotopias
细丝蛋白在脑室周围异位中的作用
- 批准号:
6361362 - 财政年份:2001
- 资助金额:
$ 28.19万 - 项目类别:
相似海外基金
PREDICTING CARIES RISK IN UNDERSERVED CHILDREN, FROM TODDLERS TO THE SCHOOL-AGE YEARS, IN PRIMARY HEALTHCARE SETTINGS
预测初级医疗保健机构中从幼儿到学龄儿童的龋齿风险
- 批准号:
10361268 - 财政年份:2021
- 资助金额:
$ 28.19万 - 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
- 批准号:
9751077 - 财政年份:2011
- 资助金额:
$ 28.19万 - 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
- 批准号:
10457019 - 财政年份:2011
- 资助金额:
$ 28.19万 - 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
- 批准号:
9976990 - 财政年份:2011
- 资助金额:
$ 28.19万 - 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
- 批准号:
10213006 - 财政年份:2011
- 资助金额:
$ 28.19万 - 项目类别: